7CA Stock Overview
A biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Camurus AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 48.66 |
| 52 Week High | SEK 62.60 |
| 52 Week Low | SEK 37.40 |
| Beta | 0.96 |
| 11 Month Change | -7.31% |
| 3 Month Change | -20.43% |
| 1 Year Change | 21.83% |
| 33 Year Change | 224.40% |
| 5 Year Change | 459.95% |
| Change since IPO | 493.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7CA | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 3.7% | 1.4% | 0.8% |
| 1Y | 21.8% | -18.4% | 9.1% |
Return vs Industry: 7CA exceeded the German Pharmaceuticals industry which returned -18.4% over the past year.
Return vs Market: 7CA exceeded the German Market which returned 9.1% over the past year.
Price Volatility
| 7CA volatility | |
|---|---|
| 7CA Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7CA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 7CA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 225 | Fredrik Tiberg | www.camurus.com |
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud’s phenomenon.
Camurus AB (publ) Fundamentals Summary
| 7CA fundamental statistics | |
|---|---|
| Market cap | €2.86b |
| Earnings (TTM) | €23.10m |
| Revenue (TTM) | €146.59m |
123.6x
P/E Ratio19.5x
P/S RatioIs 7CA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7CA income statement (TTM) | |
|---|---|
| Revenue | SEK 1.69b |
| Cost of Revenue | SEK 128.76m |
| Gross Profit | SEK 1.56b |
| Other Expenses | SEK 1.29b |
| Earnings | SEK 266.21m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | 4.53 |
| Gross Margin | 92.38% |
| Net Profit Margin | 15.76% |
| Debt/Equity Ratio | 0% |
How did 7CA perform over the long term?
See historical performance and comparison